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Multidrug resistance-associated protein-1 (MRP1) reduces the oxidative stress generated by smoking, a
risk factor for Chronic Obstructive Pulmonary Disease (COPD). We previously showed that MRP1
variants are associated with the level and decline of annual forced expiratory volume in one second
(FEV1) in the general population. Moreover, we showed that MRP1 variants are also associated with
FEV1 level and inflammatory markers in COPD patients.We investigate in the current study the
association of MRP1 protein expression in bronchial biopsies with FEV1 decline in COPD patients using
placebo, or inhaled corticosteroids (ICS) with or without long-acting b2-agonists. Additionally we
investigate the association of MRP1 variants with FEV1 decline. MRP1 variants (rs212093, rs4148382,
rs504348, rs4781699, rs35621) were genotyped in 110 COPD patients. Associations of MRP1 variants
and MRP1 protein expression in bronchial biopsies (obtained at baseline, 6 and 30 months) with FEV1
decline were analyzed using linear mixed-effect models. During 30-month ICS treatment, subjects with
a moderate staining for MRP1 had less FEV1 decline than those with a weak staining. In subjects
stopping ICS after 6 months followed by 24-month placebo, moderate staining for MRP1 was associated
with faster FEV1 decline than in those with a weak staining. None of the variants was associated with
FEV1 decline. Our unique study suggests a role of MRP1 protein expression in bronchial biopsies in FEV1
decline occurring selectively in COPD patients with long-term (30-month) ICS therapy.
& 2012 Elsevier B.V. All rights reserved.1. Introduction
Chronic Obstructive Pulmonary Disease (COPD) is an inflam-
matory disease characterized by airflow limitation that is not fully
reversible, progressive in nature and associated with an abnormal
inflammatory response of the lungs to cigarette smoke (Celli and
MacNee, 2004). Smoking is associated with accelerated lung
function decline, which can be tempered by quitting smoking.
Smoking generates oxidative stress in the lung, which can be
reduced by proteins of the ATP-binding cassette (ABC) super-
family such as multidrug resistance-associated protein 1 (MRP1)
(Cole et al., 1992). MRP1 (official name ABCC1, ABC subfamily C,
member 1) is highly expressed in human lung tissue (Cole et al.,
1992), especially at the basolateral side of bronchial epithelium
(Van der Deen et al., 2005). MRP1’s contribution varies fromll rights reserved.
: þ31 50 3614493.
.
protecting cells within the body against drugs, environmental
toxins and heavy metals, to its involvement in the cellular
oxidative defense system and inflammation (Hipfner et al., 1999
and Leslie et al. 2001).
In a recent study we showed that the MRP1 gene is associated
with the lung function in two independent general population-
based cohorts (Siedlinski et al., 2009). In these cohorts five single
nucleotide polymorphisms (SNPs) in the MRP1 gene (rs212093,
rs4148382, rs504348, rs4781699 and rs35621) were significantly
associated with level of forced expiratory volume in one second
(FEV1) or with annual FEV1 decline (Siedlinski et al., 2009). In a
subsequent study in COPD patients we have shown that the MRP1
gene plays a role in the severity of COPD, since rs212093 and
rs4148382 in MRP1 were associated with less respectively more
airway wall inflammation and a higher respectively lower level of
lung function (Budulac et al., 2010). Moreover, rs4148382 was
significantly associated with a higher MRP1 protein expression in
bronchial biopsies from subjects with established COPD (Budulac
et al., 2010). Due to these novel results with respect to the MRP1
S.E Budulac et al. / European Journal of Pharmacology 696 (2012) 136–142 137gene and severity of COPD, we aim in the current study to
investigate in depth MRP1 protein expression and lung function
in the same group of COPD patients.
Thus, consequently, our current study will focus on the
associations MRP1 protein expression in airway wall biopsies
with the decline of lung function in the same population of COPD
patients we previously studied with respect to anti-inflammatory
and clinical effects of inhaled corticosteroids (ICS) with or without
long-acting b-agonists (LABAs) (Lapperre et al., 2009). We inves-
tigated whether MRP1 protein expression in bronchial biopsies
obtained at baseline and at 6- and 30-month treatment, are
associated with the FEV1 level at baseline, 6 and 30 months and
whether MRP1 protein expression in bronchial biopsies is asso-
ciated with the course of FEV1, with and without ICS7LABA
treatment. Additionally, we investigated whether MRP1 SNPs are
associated with the course of FEV1.Table 1
Clinical characteristics of COPD patients.
Baseline characteristics, n¼114
Males, n (%) 99 (86.8)
Age (years) 61.6 (7.7)
Height (cm) 175.5 (7.8)
Packyearsa 41.8 (31.2–54.7)
Current smoker, n (%) 72 (63.2)
FEV1/FVC (%) postbronchodilator 50.3 (8.9)
FEV1 (L) postbronchodilator 2.03 (0.5)
FEV1% predicted postbronchodilator 62.7 (9.1)
Treatment groups, n¼101 (%)b
Placebo 24 (23.8)
Fluticasone 6 months, Placebo 24 months 26 (25.7)
Fluticasone 30 months 26 (25.7)
Fluticasone/Salmeterol 25 (24.8)
Data are presented as mean (S.D.) or
a median (25th–75th percentile);
b number of patients who adhered to therapy (used 470% medication);
FEV1¼forced expiratory volume in one second; FEV1/FVC¼FEV1/forced vital
capacity.2. Materials and methods
2.1. Study population
We included 114 patients with COPD who participated in a
two-center trial (Groningen Leiden Universities and Corticosteroids
in Obstructive Lung Disease; GLUCOLD study). Patient character-
istics and methods have been described in detail previously
(Lapperre et al., 2004). In brief, all patients had irreversible airflow
limitation, chronic respiratory symptoms (Lapperre et al., 2007),
did not use a course of oral steroids during the previous 3 months
and had no maintenance treatment with inhaled or oral steroids
during the previous 6 months. They were current or ex-smokers
with a smoking history of Z10 pack-years, aged between 45 and
75 years without a history of asthma. The study was approved by
the medical ethics committees of the University Medical Centers of
Leiden and Groningen. All patients gave their written informed
consent.
2.1.1. Clinical characteristics
Reversibility to salbutamol was measured at baseline, 6 and 30
months and FEV1 postbronchodilator was measured every three
months using standardized protocols (Lapperre et al., 2006).
2.1.2. Intervention and follow-up procedures
Patients were randomly assigned to receive either: (1) flutica-
sone propionate, 500 mg twice daily, for the first 6 months
followed by placebo, twice daily, for 24 months; (2) fluticasone,
500 mg twice daily for 30 months; (3) fluticasone, 500 mg twice
daily and salmeterol, 50 mg twice daily, in a single inhaler for
30 months; (4) placebo, twice daily, for 30 months (Lapperre
et al., 2009).
2.2. MRP1 tagging SNPs and genotyping
We selected from all MRP1 tagging SNPs rs212093, rs4148382,
rs35621, rs4781699 and rs504348 based on our previous studies
showing a significant associations with FEV1 level and/or annual
FEV1 decline in the general population (Siedlinski et al., 2009), as
well as with FEV1 level and inflammatory markers in COPD
patients (Budulac et al., 2010). Genotyping was performed by
K-Bioscience (UK) using their patent-protected competitive allele
specific PCR system (KASPar).
2.3. Biopsies and immunohistochemistry on bronchial biopsies
Details on fiberoptic bronchoscopy, biopsy processing and
immunohistochemical staining are described in the datasupplement (additional file 1; subsections 2.3.1, 2.3.2 and 2.3.3).
MRP1 protein was scored for staining intensity in intact epithe-
lium of bronchial biopsies with a semiquantitative score: 1¼no or
weak; 2¼moderate; 3¼strong staining intensity.2.4. Statistics
Differences between treatment groups in MRP1 staining
intensity at baseline, 6 and 30 months were analyzed using Chi-
square tests (see additional file 1 for details; subsection 2.4.1).
We assessed the association of MRP1 protein expression at
baseline, 6 months and 30 months with the FEV1 levels at those
time points using linear mixed-effect models (LME) stratified for
treatment group, with adjustment for gender, height and age at
baseline.
We used LME models to assess the association of MRP1 protein
expression at baseline with FEV1 decline stratified for treatment
groups, separately for the period till 6 months and the time after
6 months because of the change in treatment for one of the
groups. We adjusted our analyses for height and age at baseline,
gender and the interaction of time with age at baseline and
gender.
We assessed the associations of MRP1 SNPs with FEV1 decline
using LME models (see additional file 1 for details on the genetic
model; subsection 2.4.1). Analyses were adjusted for height and
age at baseline, gender, treatment and the interactions of time
with age at baseline, gender and treatment.
Analyses were performed using SPSS version 16.0 for Windows
and values of po0.05 (tested 2-sided) were considered statisti-
cally significant. Linkage Disequilibrium (LD) plots a threshold
of 0.8 for the correlation coefficient (r2) and Hardy Weinberg
Equilibrium (HWE) tests were performed with Haploview (ver-
sion 4.2) (Barrett et al., 2005).3. Results
The clinical characteristics of COPD patients are presented in
Table 1.
All 5 MRP1 SNPs were in Hardy Weinberg Equilibrium (HWE,
p40.05) and were only weakly correlated with each other; the
highest r2 in our population being 0.34 (Fig. 1).
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within treatment groups.
There were no consistent differences between treatment
groups in MRP1 staining intensity at baseline, 6 and 30 months.
There were no differences in age, lung function and packyears
between subjects with at least 1 biopsy with intact epithelium
(n¼91 (79.8%)) and those without any biopsy (n¼23 (20.2%)).
There were fewer women with at least 1 biopsy with intact
epithelium (n¼9 (64.3%)) than men (n¼77 (88.5%)).3.1. MRP1 protein expression and FEV1 level at 0, 6 and 30 months
MRP1 protein expression at 0, 6 and 30 months was not
significantly associated with FEV1 levels at those time points
(detailed results are presented in the table S1; additional file 1).3.2. MRP1 protein expression at baseline and FEV1 decline
(0–6 months and 6–30 months)
Subjects with a moderate or strong intensity of staining for
MRP1 protein expression at baseline did not have a slower or
faster FEV1 decline compared to those with weak staining forFig. 1. Linkage disequilibrium plot and correlation coefficients (r2) for the 5 MRP1
polymorphisms genotyped in COPD patients (n¼110). MRP1¼multidrug resis-
tance-associated protein-1 (official name ABCC1, ATP-binding cassette (ABC) sub-
family C, member 1); the location of the single nucleotide polymorphisms is given
for the HapMap Data Release February 2009.
Table 2
Frequencies of MRP1 staining intensity levels within treatment groups.
Treatment group MRP1 scores baseline MRP1 s
1a 2b 3c Ntd 1a
Placebo, N 3 8 2 13 3
Fluticasone 6 months, N 3 8 3 14 3
Fluticasone 30 months, N 3 8 4 15 1
Fluticasone/Salmeterol, N 8 2 1 11 3




d Nt¼total number of subjects per treatment group for each time point.MRP1 protein expression in any of the treatment groups for the
ensuing period of 6-month treatment (Fig. 2).
In the group with 30-month ICS treatment, subjects having a
moderate intensity of staining at baseline had less FEV1 decline
between 6 and 30 months than those with a weak intensity of
staining for MRP1 protein (Fig. 2). Conversely, in the treatment
group with discontinuation of ICS therapy after 6 months, sub-
jects having a moderate intensity of staining had a faster FEV1
decline compared to those with a weak intensity of staining for
MRP1 protein (Fig. 2).
MRP1 protein expression at baseline was not significantly
predictive of 30-month FEV1 decline in the group using placebo
or combination of LABAs with ICS (Fig. 2).
3.3. MRP1 SNPs and FEV1 decline (0–6 months and 6–30 months)
None of the MRP1 SNPs was significantly associated with the
FEV1 decline for either the period till 6 months or the time after
6 months (Fig. 3).
Additional adjustment for the initial FEV1 and its interaction
with time did not change the size or significance of the estimated
effect of the genotypes on FEV1 decline.4. Discussion
This is the first study showing significant associations of a
higher MRP1 protein expression with less accelerated FEV1
decline in COPD patients using long-term therapy with ICS and
a significant association of higher MRP1 protein expression with a
faster FEV1 decline after withdrawal of ICS. These associations
were not likely due to the genetic background in MRP1, since the
SNPs in MRP1 that were previously associated with the level of
FEV1 (Budulac et al., 2010), in the current study are not signifi-
cantly associated with FEV1 decline in the same group of
COPD patients. This is in line with our previous findings show-
ing that the same two SNPs are not significantly associated
with the decline of lung function in the general population
(Siedlinski et al., 2009) suggesting that these SNPs may play a
role in COPD severity, without any further effects on lung function
over time.
Current international guidelines recommend maintenance
therapy with LABAs and ICS in moderate to severe COPD with
exacerbations (Rabe et al., 2007). Variable findings have been
published regarding the effect of ICS on lung function (decline)
and exacerbations in COPD. In one study, fluticasone propionate
and salmeterol significantly improved lung function after 2-week
treatment and this effect was sustained during 12-month treat-
ment (Calverley et al., 2003). Although some other studies
showed no effect of fluticasone propionate or budesonide on lung
function in COPD patients (Burge et al., 2000; Hattotuwa et al.,cores 6 months MRP1 scores 30 months
2b 3c Ntd 1a 2b 3c Ntd
6 4 13 1 9 3 13
10 5 18 3 13 2 18
12 4 17 3 8 1 12
11 1 15 1 12 6 19
Fig. 3. The effect of MRP1 SNPs on FEV1 decline (0–6 months, 6–30 months). The upper graph is for the first 6 months and the lower graph is for the period from 6 to 30
months. FEV1¼forced expiratory volume in one second. Squares represent the regression coefficient (B) and vertical bars the 95% confidence interval (CI). Wild type was
set to zero as the reference category. Different numbers for the SNP genotypes are due to missing data on genotype or FEV1 measurements at every time point. The
analyses are adjusted to height and age at baseline, gender, treatment and the interactions of time with age at baseline, gender and treatment.
Fig. 2. The effect of MRP1 protein level at baseline on FEV1 decline. The upper graph is for the first 6 months and the lower graph is for the period from 6 to 30 months.
FEV1¼forced expiratory volume in one second. Squares represent the regression coefficient (B) and vertical bars the 95% confidence interval (CI). The weak staining for
MRP1 was set to zero as the reference category. The analyses are adjusted for height, age at baseline, gender and the interaction of time with gender and age at baseline.
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suggest that disease progression can be modified by ICS (Celli
et al., 2008; Lapperre et al., 2009; Van der Valk et al., 2002 and
Wouters et al., 2005). Our current study provides further informa-
tion in that those subjects with a moderate staining for MRP1
level had less lung function decline compared to those with a
weak staining in the presence of long-term (30-month) therapy
with fluticasone propionate. Importantly, subjects with a moder-
ate intensity of MRP1 staining who stopped fluticasone treatmentat 6 months and subsequently used 24-month placebo, had a
significantly faster lung function decline compared with those
with a weak staining for MRP1. This suggests that continuing
therapy with ICS may positively influence the association of MRP1
protein with FEV1 decline. Furthermore, an in vitro study showed
that FP accelerated the conversion of leukotriene C4 (LTC4) to
LTD4 and finally leaded to the accelerated degradation of LTC4 to
less active LTE4 via LTD4 and this action was observed only after
cells were exposed to FP for more than 2 days, suggesting new
S.E Budulac et al. / European Journal of Pharmacology 696 (2012) 136–142140protein synthesis (Zaitsu et al., 2001). The authors speculated that
regular use of FP up-regulates the catabolic process of LTC4 to less
active LTE4, and therefore contributes to the antiasthma actions
(Zaitsu et al., 2001). Although the inflammatory processes occur-
ring in asthma and COPD are different, we can speculate that in
the current in vivo study, stopping ICS therapy after 6 months
could have a negative effect on the action of the MRP1 protein
substrate LTC4. Also this is suggestive of an interaction between
long-term therapy with ICS and MRP1 function. We did not
investigate the effect of specific treatment on MRP1 protein
expression in bronchial biopsies (Van der Deen et al., 2008 and
Bandi and Kompella, 2002), therefore it is uncertain whether this
association of MRP1 protein with lung function decline in the
presence of long-term therapy with fluticasone results from the
effect of treatment or from MRP1 functionality and/or activity.
Further studies, that might include smoking animal models,
should also focus on the effect of bronchial epithelium MRP1
protein level in the presence of COPD medication such as
fluticasone propionate. Whereas in previous studies in a smoking
animal model we studied the association of bronchial MRP1
expression and inflammation (Van der Deen et al., 2007), it would
be of interest in future studies to also focus in COPD/smoking-
related animal models on the association of bronchial MRP1
protein and lung function.
A previous study showed that the therapy with salmeterol plus
fluticasone propionate, or with salmeterol and fluticasone pro-
pionate separately reduces the rate of decline of FEV1 in patients
with moderate-to-severe COPD (Celli et al., 2008). Prior, we
showed in the current COPD patients (GLUCOLD) that combina-
tion therapy of fluticasone propionate and salmeterol when
compared with fluticasone alone has no additional long-lasting
effects on inflammatory cells and that it improves FEV1 level
without further influencing FEV1 decline (Lapperre et al., 2009).
These observations may indicate that disease modification may
occur in particular sub phenotypes of patients with COPD
(Lapperre et al., 2009). Our data suggest that MRP1 protein
expression may reflect one of the COPD phenotypes that is
sensitive to inhaled corticosteroid therapy. In fact that we did
not find a significant association of MRP1 protein expression with
30-month FEV1 decline in the group using combination of LABA
with ICS is likely due to lack of power. Unfortunately, only
2 subjects had analyzable biopsies with a moderate staining for
MRP1 protein at baseline in the group randomly selected to use
combination of LABAs with ICS.
MRP1 is located in bronchial epithelium, which is the first
line of defense against invading microorganisms and inhaled
toxic substances like cigarette smoke. Moreover, epithelial cells
are the first cells that pulmonary drugs have to come across to
reach the underlying tissue and act on it. Thus MRP1 may have a
role in development and severity of COPD. We have previously
shown that patients with moderate and severe COPD have a
lower MRP1 expression in bronchial biopsies than healthy
individuals. Furthermore, patients with severe and very severe
COPD had again a lower intensity of MRP1 protein expression
than those with mild and moderate severe COPD (Van der Deen
et al., 2006). Thus the spectrum of MRP1 protein expression
reaches from higher in healthy subjects to lower in severe
disease. Although our previous study (Van der Deen et al.,
2006) is not comparable with our current study due to differ-
ences in study design and type of biopsies used for analyses (e.g.
frozen vs. paraffin), it is tempting to speculate that the observed
association of a higher MRP1 protein expression with a less rapid
FEV1 decline fits with our COPD patients having mild to moder-
ate COPD. This might also explain why we did not observe any
significant association of an even higher MRP1 protein expres-
sion (coded as strong) with FEV1 decline (Fig. 1). The ultimateeffect may, as our data suggest, depend on the medication
prescribed, as likely as on doses and time of administration.
These findings are of importance since they can contribute to
pharmacogenetics of COPD management in mild to moderate
COPD patients, which will result in more accurate and targeted
therapy.
We showed previously in an in vitro study that cellular
concentrations of budesonide affect negatively MRP1 function,
likely by inhibiting MRP1 mediated transport that protects
against oxidative stress and toxic compounds (Van der Deen
et al., 2008). How can we reconcile this with our current findings
that a higher MRP1 protein expression is associated with less
accelerated lung function decline in subjects using 30-month
fluticasone propionate therapy? We can speculate on some
possible explanations. First, the deposition of drugs may influence
its effects. A human in vivo study demonstrated that fluticasone
propionate concentrations are three times higher in central than
peripheral lung tissue (Esmailpour et al., 1997). Moreover, the
same study showed (Esmailpour et al., 1997) that fluticasone
concentrations in peripheral lung tissue following inhalation of a
1.0 mg dose were higher compared to those reported for bude-
sonide (Van den Bosch et al., 1993). Thus, there may be dose
differences between our previously published in vitro study on
effects of budesonide and the doses present in the airways and
lung tissue with fluticasone in vivo.
Second, the action of different inhaled corticosteroids on
epithelial tissue may depend on the pharmacokinetic and phar-
macodynamic properties of their components. For example,
budesonide is less lipophilic than fluticasone and therefore is
dissolving freely in airway mucus and is more rapidly absorbed
into the airway tissue (Brattsand and Miller-Larsson, 2003 and
Thorsson et al., 2001) whereas fluticasone propionate is released
slower from the lung lipid compartment with a longer local
duration of action (Johnson, 1998). Thus the duration of action
of each inhaled steroid may affect the outcome on MRP1 protein
association and lung function decline.
Third, it has been previously shown that MRP1 substrates
identified by vesicle transport studies compete with each other
for transport, even if there are no similarities between the
compounds and they are conjugated to different anionic moieties,
e.g. LTC4 or E217bG (Loe et al., 1996a, 1996b). This suggests
that each substrate is creating an exclusive interaction with MRP1
and it might be that fluticasone propionate and budesonide act
also differently in the presence of this protein by being involved
in different competing activities with other transported
substrates.
We believe that our unique study, due to its clear design and
including lung function measurements and biopsy data, has
brought new ideas on a possible role of MRP1. This needs further
investigation, since is seems possible that MRP1 is differentially
influenced by different types of ICS. Our data suggest further
exploration of MRP1 in a larger group to establish whether MRP1
could be a candidate marker for individualized ICS prescription
in COPD.5. Conclusions
In conclusion, this is the first study showing a protective
association of a moderate MRP1 protein level in bronchial
biopsies with lung function decline in COPD patients using
long-term maintenance therapy with fluticasone propionate,
when compared with COPD patients having a low intensity of
MRP1 protein staining. Conversely, a deleterious association was
present when ICS therapy was discontinued after 6-month treat-
ment with fluticasone.
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